First: a once-weekly subcutaneous injection of semaglutide 1.0 mg called Ozempic, a GLP-1, was approved for the treatment of type 2 diabetes, and has proven to reduce the risk of cardiovascular events in people with type 2 diabetes and cardiovascular disease.
Then following this, the groundbreaking STEP 1 Trial, demonstrated that a higher dose of semaglutide, 2.4 mg (now known as Wegovy) could result in unbelievable weight loss and improvements in cardiometabolic health! They significantly decreased their waist circumference, their blood pressure, inflammatory markers, blood sugar markers such as HgbA1c, fasting plasma glucose, and serum insulin, and their triglycerides!
The individuals on semaglutide had almost 15% weight loss in 68 weeks, compared to just 2.4% weight loss in the placebo group!